Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

* Statistically significant reduction in sedation during the early post-operative period compared to morphine

* Statistically significant reduction in nausea in the female patient population compared to morphine

Cambridge, UK, 8th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company, announces additional data from post-hoc analysis of the recent Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. The Phase III data released on 20 February 2007 confirmed M6G's planned product profile and showed that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).

Sedation

Analysis of the sedation data from the M6G022 trial showed statistically significant reductions in sedation in the M6G group compared to morphine in the first four hours after surgery reaching a reduction of 15% at 4 hours (p=0.007). Discussions with clinicians support the view that this is a clinically important benefit. Opiates such as morphine are well known to induce sedation and respiratory depression. Excessive sedation in the early post-operative period is associated with depression of the respiratory system, which can, in some cases, be fatal.

Nausea in female patients

It is well established that female patients undergoing surgery have a higher risk of experiencing nausea and vomiting in the post-operative period. New data analysing the female patient group (approximately 70% of the patients in the M6G022 Phase III clinical trial) showed a statistically significant reduction in nausea in the period 6-24 hours after treatment (p=0.034). The overall incidence and severity of post-operative nausea in the M6G arm for both males and females was 27% less than that observed in the morphine arm but narrowly missed statistical significance, p=0.052 (versu
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:12/15/2009)... Harvard medical expert internationally recognized as a leading ... decision last month to suspend Doug Barron for ... having the medical condition hypogonadism and ... unfair and discriminatory." ,, Hypogonadism is ... often referred to informally as Low T ...
(Date:12/15/2009)... -- Fenwal Inc., a global medical technology company ... availability, announced today that the U.S. Food and ... InterSol ® platelet additive solution. Fenwal ... specialized product used in combination with human plasma ... used to prevent or treat bleeding. ,, InterSol ...
(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, Boehringer Ingelheim GmbH: PharmaVitae Profile ... Introduction ,, This analysis examines the ... in the Rx pharmaceutical sector. The profile ... and assessment of financial performance, with 1-6 ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Fenwal Receives FDA Approval for New Solution Used to Store Donated Blood Platelets 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7Heart Attacks Less Often Fatal Today 49550 1Heart Attacks Less Often Fatal Today 49550 2Heart Attacks Less Often Fatal Today 49550 3EUROPACE raises remote monitoring profile 49546 1EUROPACE raises remote monitoring profile 49546 2EUROPACE raises remote monitoring profile 49546 3Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 1Governor Rendell Discusses Impact of Budget on Services for Families of Children With Autism 49543 2
... Scheduled for Friday, May 4, at 9:00 a.m.,Eastern ... 2007 /PRNewswire-FirstCall/ --,Medivation, Inc. today announced that new ... disease patients in the Company's,six-month Phase 2 efficacy ... compared with placebo-treated patients on,all five efficacy endpoints ...
... Homspera Shows Promise As an Adjuvant for ... Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IR,BioSciences ... its influenza vaccine adjuvant study being performed ... host,immune responsiveness above that induced by vaccine ...
Other Medicine Technology:Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 2Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 3Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 4Medivation Announces Presentation of New Subset Analyses From,Dimebon Phase 2 Alzheimer's Disease Trial at American Academy of,Neurology Annual Meeting 5IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 2IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 3IR BioSciences Announces Promising Data from Study of Its Compound,Homspera 4
(Date:12/15/2009)... -- Palo Alto Networks(TM), the network security company, ... PA-4000 Series next-generation firewalls for accurate threat prevention ... and control over applications such as peer-to-peer file ... university with eight facilities on five campuses. The ... number of academic schools and institutions throughout Japan. ...
(Date:12/15/2009)... the Lupus Foundation of America and the Saint Thomas, ... -- Julian Lennon, son of the legendary John Lennon, ... single, "LUCY," to raise funds for research on the ... percent of the proceeds from downloading "LUCY" at iTunes ... (LFA), and the Saint Thomas, Lupus Trust in Great ...
(Date:12/15/2009)... Dec. 15 Vitech Systems Group, a ... Management (CRM) software, announced today that it has ... for the Screen Actors Guild-Producers Pension & Health ... customer service capabilities to SAG-PH call center personnel ... was installed using Vitech,s V3 Benefits Administration System ...
(Date:12/15/2009)... associated with lower dementia risk, research finds , , TUESDAY, ... leptin, a hormone that regulates appetite, may guard against ... or 15 years this may be one of many ... Alzheimer,s disease," said senior study author Dr. Sudha Seshadri, ... of Medicine. "Or it may be one of many ...
(Date:12/15/2009)... doses have lower strength than needed for protection, CDC ... 800,000 children,s doses of H1N1 swine flu vaccine have ... have lost some potency, federal health officials said Tuesday. ... and Prevention, the company,s routine testing of the vaccine ... found that four batches had lower than required potency ...
Breaking Medicine News(10 mins):Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 2Health News:Palo Alto Networks Next-Generation Firewalls Deliver High-Performance Network Protection for Shinshu University 3Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:Fat Hormone May Protect Against Alzheimer's 2Health News:Fat Hormone May Protect Against Alzheimer's 3Health News:Large Recall of Children's Swine Flu Vaccine 2
... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... its financial results for the fourth quarter and full year ... the opening of the financial markets.NxStage will also host a ... 12, 2009 to discuss its fourth quarter and year end ...
... Former Director of National Institutes of HealthNEW YORK, Feb. 3 ... today the election of Dr. Elias A. Zerhouni , ... and leader in biomedical research, to its Board of Directors."We ... Board of Directors," said Dr. Maria C. Freire , ...
... Chief Marketing Officer and PACS Industry Veteran ... Feb. 3 Compressus, Inc., leaders in healthcare ... with the promotion of Janine Broda to chief ... Gibbons as vice president and general manager of ...
... Female Health Company (NYSE Alternext: FHC) today announced that ... its operating results for the first quarter of FY2009 ... 10, 2009. The Company plans to report its ... and other interested parties may participate in the conference ...
... Healthy, Inc. (Pink Sheets: GOHE) announced today that the ... development of major sports relationships at meetings held in ... partnership with a sports entity, whose members are among ... a major extension of our agreement with Athletic International ...
... best way of spotting trouble, experts say , , TUESDAY, ... stool-based colon cancer tests -- recommended annually for Americans ... spot potential abnormalities, a German study finds. , Doctors ... for what is called fecal occult blood -- otherwise ...
Other Medicine News:Health News:NxStage to Report Fourth Quarter and Full Year 2008 Financial Results 2Health News:Lasker Foundation Welcomes Elias Zerhouni to Board of Directors 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 2Health News:Compressus Bolsters Executive Team to Expand Interoperability Market Pioneered by MEDxConnect(TM) 3Health News:The Female Health Company Schedules First Quarter Conference Call for February 10, 2009 2Health News:Go Healthy Participates in Super Bowl Events and Developing Sports Relationships 2Health News:Stool-Based Colon Cancer Tests Vary Widely in Accuracy 2Health News:Stool-Based Colon Cancer Tests Vary Widely in Accuracy 3
... are the latest innovation ... portable battery-powered EEG headboxes. ... new mechanical design, and ... standard MOBEE24plus and MOBEE32 ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: